NodThera Announces First Patients Dosed in a Phase Ib/IIa Cardiovascular Risk Trial of NLRP3 Inflammasome Inhibitor NT-0796
October 16, 2023
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces that the first patients have been